Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 3/20 | 0.37 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.35 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30748702 | 1.00 | KMT2A (0.52) | KMT2AEPHX2LMNASMN1; SMN2CASP3 | |
| SCHEMBL25390706 | 1.00 | KMT2A (0.52) | KMT2AEPHX2LMNASMN1; SMN2CASP3 | |
| SCHEMBL16942065 | 1.00 | KMT2A (0.52) | KMT2AEPHX2LMNASMN1; SMN2CASP3 | |
| SCHEMBL22342591 | 0.92 | KMT2A (0.49) | KMT2AEPHX2LMNASMN1; SMN2CASP3 | |
| SCHEMBL3087950 | 0.89 | KMT2A (0.58) | KMT2AEPHX2CASP3 | |
| SCHEMBL26032361 | 0.87 | KMT2A (0.58) | KMT2AEPHX2LMNASMN1; SMN2CASP3 | |
| SCHEMBL7855942 | 0.85 | KMT2A (0.69) | KMT2AEPHX2CASP3TLR2TLR1 | |
| SCHEMBL31657114 | 0.85 | CASP3 (0.41) | KMT2ACASP3TLR2 | |
| SCHEMBL22279559 | 0.84 | KMT2A (0.59) | KMT2AEPHX2LMNASMN1; SMN2CASP3 | |
| SCHEMBL15146937 | 0.84 | KMT2A (0.59) | KMT2AEPHX2LMNASMN1; SMN2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187745-B2 | Camptothecine antibody-drug conjugates and methods of use thereof | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4377319-A2 | ANTIBODIES AND ANTIBODY CONJUGATES SPECIFIC FOR NECTIN-4 AND METHODS OF USE THEREOF | R.P. Scherer Technologies, LLC (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-117279662-A | Branched linkers for antibody-drug conjugates and methods of use thereof | R.P.谢勒技术有限责任公司 | 2023-12-22 | — | — | CN | disclosed |
| US-20230277676-A1 | CAMPTOTHECINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2023-09-07 | — | — | US | disclosed |
| WO-2023009751-A2 | ANTIBODIES AND ANTIBODY CONJUGATES SPECIFIC FOR NECTIN-4 AND METHODS OF USE THEREOF | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277676-A1 | CAMPTOTHECINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | DCTD, ADCY8, ADCY3 | KMT2A 1187/4885EPHX2 931/4885LMNA 3396/4885 |
| US-12187745-B2 | Camptothecine antibody-drug conjugates and methods of use thereof | DCTD, ADCY8, ADCY3 | KMT2A 1187/4885EPHX2 931/4885LMNA 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.